Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria

Basit Öğe Kaydı
dc.contributor.authorDumlu, Rıdvan
dc.contributor.authorYurttutan Uyar, Neval
dc.contributor.authorAyaş, Meltem
dc.contributor.authorAksoy, Nilay
dc.contributor.authorÖztürk, Nur
dc.contributor.authorKocagöz, Ayşe Sesin
dc.date.accessioned2023-01-08T08:22:01Z
dc.date.available2023-01-08T08:22:01Z
dc.date.issued2022en_US
dc.departmentFakülteler, Eczacılık Meslek Bilimleri Bölümü, Klinik Eczacılık Ana Bilim Dalıen_US
dc.description.abstractBackground/aim: Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its resistance by analyzing gram-negative bacteria isolated from various patient samples. Materials and methods: Between March and November 2020, 1119 gram-negative bacteria strains were isolated from patient samples in Acıbadem Healthcare Group hospitals; ceftazidime-avibactam susceptibility results were evaluated using a 10/4µg (Oxoid, UK) disc and evaluated according to Eucast 2020 recommendations. Patient and isolate characteristics that could be risk factors were retrospectively investigated and statistically analyzed using SPSS 25.0. Results: Male patients made up 52% (n = 581) of the study’s total patient population, and they averaged 55.5 ± 24.9 years old. Of 1119 gram-negative strains culture and antibiogram, 1023 (91.4%) were sensitive to ceftazidime-avibactam. An increased risk of resistance was observed with female gender (OR = 2.29; CI 95% [1.45–3.61]; p < 0.05), Pseudomonas aeruginosa (OR = 1.67, CI 95% [1.03–2.7]; p < 0.05), the presence of multidrug-resistance (MDR) (OR = 4.07, CI 95% [2.47–6.7]; p < 0.05) pandrug-resistance (PDR) (OR = 12, (CI) 95% [9.9–14.7] ]; p < 0.05) and admission to intensive care unit (ICU) (OR = 1.89, CI 95% [1.22–2.93]; p < 0.05). Conclusion: The resistance rate of ceftazidime-avibactam was found to be 8.6%, and it was thought that resistant strains produced metallo-ß-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pseudomonas aeruginosa, MDR, PDR, and admission to ICU. Therefore, studying the ceftazidime-avibactam susceptibility test together with gram-negative bacteria identification, especially in groups at risk for resistance, is one of the important factors that can positively affect the success of treatment.en_US
dc.identifier.citationDumlu, R., Uyar, N. Y., Ayaş, M., Aksoy, N., Öztürk, N., Kocagöz, A. S. (2022). Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria. Turkish Journal of Medical Sciences, 52(6), 1839-1844.en_US
dc.identifier.endpage1844en_US
dc.identifier.issn1300-0144
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85144503666
dc.identifier.scopusqualityQ1
dc.identifier.startpage1839en_US
dc.identifier.trdizinid1145646
dc.identifier.urihttps://hdl.handle.net/20.500.12939/3173
dc.identifier.volume52en_US
dc.identifier.wosWOS:000906716200012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorAksoy, Nilay
dc.language.isoen
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.isversionof10.55730/1300-0144.5530en_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAntimicrobial Agentsen_US
dc.subjectCeftazidime-Avibactam Combinationen_US
dc.subjectDrug-Resistanten_US
dc.subjectGram-Negative Bacteriaen_US
dc.subjectMultidrug-Resistanten_US
dc.titleInvestigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Investigation of ceftazidime-avibactam susceptibility in clinical.pdf
Boyut:
239.27 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu